Tango Therapeutics Reports Widened Q1 Net Loss of $45.5M as Collaboration Revenue Falls to Zero
TNGX has more than doubled off its 52-week low of $1.25.
Summary
Tango Therapeutics reported a widened Q1 net loss of $45.51 million, primarily due to collaboration revenue falling to zero from $5.4 million in the prior year. This significant decline in revenue is a direct result of the Gilead agreement ending and all deferred revenue being recognized in 2025. While R&D expenses saw a decrease from discontinued programs, general and administrative costs increased. Despite these negative financial results, the company provided a positive outlook, projecting a cash runway into 2028, which extends beyond anticipated key data inflection points. Traders will closely monitor future clinical trial data and potential new collaboration opportunities to offset the loss of this revenue stream.
At the time of this announcement, TNGX was trading at $23.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $1.25 to $28.41. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.